Martin Gore

60.8k total citations · 12 hit papers
382 papers, 29.5k citations indexed

About

Martin Gore is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Martin Gore has authored 382 papers receiving a total of 29.5k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 147 papers in Molecular Biology and 106 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Martin Gore's work include Ovarian cancer diagnosis and treatment (104 papers), Renal cell carcinoma treatment (86 papers) and Cancer Genomics and Diagnostics (56 papers). Martin Gore is often cited by papers focused on Ovarian cancer diagnosis and treatment (104 papers), Renal cell carcinoma treatment (86 papers) and Cancer Genomics and Diagnostics (56 papers). Martin Gore collaborates with scholars based in United Kingdom, United States and France. Martin Gore's co-authors include Tim Eisen, James Larkin, Bernard Escudier, Stéphane Oudard, Cezary Szczylik, Ronald M. Bukowski, Walter M. Stadler, Thomas E. Hutson, Sylvie Négrier and Apurva A. Desai and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Martin Gore

373 papers receiving 28.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 1.5k citations A. Hilary Calvert, David R. Newell et al. Journal of Clinical Oncology profile →
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

2001 979 citations David Guthrie, Martin Gore et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 936 citations Martin Gore et al. Journal of Clinical Oncology profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

2000 858 citations Martin Gore et al. profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Samra Turajlic, Martin Gore et al. profile →
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 542 citations Bernard Escudier, Thomas E. Hutson et al. profile →
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

1997 532 citations Martin Gore, I Hudson et al. Journal of Clinical Oncology profile →
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

2011 446 citations Martin Gore et al. profile →
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations Martin Gore et al. profile →

Peers

Countries citing papers authored by Martin Gore

Since Specialization

Citations

This map shows the geographic impact of Martin Gore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gore more than expected).

Fields of papers citing papers by Martin Gore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Gore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gore. The network helps show where Martin Gore may publish in the future.

Co-authorship network of co-authors of Martin Gore

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Gore. A scholar is included among the top collaborators of Martin Gore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Gore. Martin Gore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis 2016 ·Clinical Cancer Research ·Robert E. Hawkins, Martin Gore, Yaroslav Shparyk, (unknown), Oleg Gladkov, (unknown), Mihai Hârza, (unknown), Igor Bondarenko, Petr Karlov, O. B. Kаryakin, Р. Ш. Хасанов, Gunnar Hedlund, G. Forsberg, Örjan Nordle, Timothy Eisen	23
2	Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer 2016 ·Obstetrical & Gynecological Survey ·Rosalind A. Eeles, James P. Morden, Martin Gore, Janine Mansi, J.P. Glees, M. Wenczl, Christopher Williams, Henry C Kitchener, Richard H. Osborne, David Guthrie, Peter Harper, Judith M. Bliss	0
3	Response to chemotherapy in relapsed low-grade serous ovarian carcinoma: Royal Marsden series of 46 patients 2016 ·Annals of Oncology ·Jennifer McLachlan, Nina Tunariu, João Paulo da Silveira Nogueira Lima, Angela George, Martin Gore, S.B. Kaye, Susana Banerjee	1
4	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma 2015 ·Molecular Cancer Therapeutics ·Victoria L. Bridgeman, Elaine Y. Wan, Shane Foo, Mark R. Nathan, Jonathan Welti, Sophia Frentzas, Peter Vermeulen, Natasha Preece, Caroline J. Springer, Thomas Powles, Paul Nathan, James Larkin, Martin Gore, Naveen Vasudev, Andrew R. Reynolds	38
5	Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases 2015 ·Thrombosis Research ·(unknown), Heleen J. van Beekhuizen, Vivek Nama, (unknown), Marielle Nobbenhuis, Thomas Ind, S.A. Sohaib, F. Lofts, Sue Heenan, Martin Gore, Susana Banerjee, Stan B. Kaye, Desmond P.J. Barton	14
6	The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis 2014 ·Pigment Cell & Melanoma Research ·Simon J. Furney, Samra Turajlic, Gordon Stamp, Janet Thomas, Andrew Hayes, D. Strauß, Mike Gavrielides, Xing Wei, Martin Gore, James Larkin, Richard Marais	80
7	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma 2012 ·Cancer Discovery ·María Romina Girotti, Malin Pedersen, Berta Sanchez‐Laorden, Amaya Virós, Samra Turajlic, Dan Niculescu‐Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Paul Lorigan, Caroline J. Springer, James Larkin, Claus Jørgensen, Richard Marais	272
8	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer 2012 ·Molecular Cancer Therapeutics ·Craig P. Carden, Adam Stewart, (unknown), Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B. Kaye, Udai Banerji	81
9	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies 2012 ·Clinical Cancer Research ·Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, (unknown), Mary Anne Tanay, Chris Nutting, Kate Newbold, Martin Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, K.L. Mettinger, Richard G. Vile, Hardev Pandha, Geoff Hall, Alan Melcher, John Chester, Kevin J. Harrington	151
10	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer 2011 ·Journal of Clinical Oncology ·Jonathan A. Ledermann, Allan Hackshaw, (unknown), Gordon C. Jayson, Hani Gabra, Iain A. McNeish, Helena Earl, Timothy Perren, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay E. James, Graham Temple, Michael Merger, Gordon Rustin	164
11	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
12	Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors 2008 ·Cancer Research ·Mohan Hingorani, Christine L. White, (unknown), (unknown), Martin Gore, Andrew Slade, Simon D. Scott, Christopher M. Nutting, Hardev Pandha, Alan Melcher, Richard G. Vile, Georges Vassaux, Kevin J. Harrington	20
13	Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy 2008 ·Clinical Cancer Research ·Mohan Hingorani, Christine L. White, Shane Zaidi, (unknown), (unknown), Martin Gore, Christopher M. Nutting, Hardev Pandha, Alan Melcher, Richard G. Vile, Georges Vassaux, Kevin J. Harrington	29
14	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794
15	High-Risk Premenopausal Women's Experiences of Undergoing Prophylactic Oophorectomy: A Descriptive Study 2004 ·Genetic Testing ·Nina Hallowell, James Mackay, Martin Richards, Martin Gore, Ian Jacobs	25
16	ICON2 trial (multiple letter) [1] 1999 ·The Lancet ·Martine Piccart, William P. McGuire, Martin Gore, (unknown), Valter Torri, Nicoletta Colombo, (unknown), Josie Sandercock	0
17	Experience with independent radiological review during a topotecan trial in ovarian cancer 1997 ·Annals of Oncology ·(unknown), Giorgio Bolis, Martin Gore, W. ten Bokkel Huinink, Jaap Verweij, I Hudson, Raymond Despax, (unknown)	26
18	Immunotherapy in cancer 1996 ·John Wiley eBooks ·Martin Gore, P G Riches	6
19	Carboplatin dosage: prospective evaluation of a simple formula based on renal function. breakdown → 1989 ·Journal of Clinical Oncology ·A. Hilary Calvert, David R. Newell, Lindsey Gumbrell, Séamus O’Reilly, Matthew Burnell, Frances Boxall, Zahid H. Siddik, Ian Judson, Martin Gore, E. Wiltshaw	1510
20	A phase II study of mitozantrone in advanced carcinoma of the ovary 1989 ·Cancer Chemotherapy and Pharmacology ·Robert E. Coleman, (unknown), Martin Gore, E. Wiltshaw, M L Slevin, Peter Harper	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact